217 related articles for article (PubMed ID: 18653827)
1. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.
Chan KC; Lai PB; Mok TS; Chan HL; Ding C; Yeung SW; Lo YM
Clin Chem; 2008 Sep; 54(9):1528-36. PubMed ID: 18653827
[TBL] [Abstract][Full Text] [Related]
2. Combination of serum RASSF1A methylation and AFP is a promising non-invasive biomarker for HCC patient with chronic HBV infection.
Dong X; He H; Zhang W; Yu D; Wang X; Chen Y
Diagn Pathol; 2015 Aug; 10():133. PubMed ID: 26238200
[TBL] [Abstract][Full Text] [Related]
3. Methylation of tumour suppressor genes
El-Bendary M; Nour D; Arafa M; Neamatallah M
Br J Biomed Sci; 2020 Jan; 77(1):35-40. PubMed ID: 31790342
[No Abstract] [Full Text] [Related]
4. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma.
Pasha HF; Mohamed RH; Radwan MI
Cancer Biomark; 2019; 24(2):241-247. PubMed ID: 30689554
[TBL] [Abstract][Full Text] [Related]
5. Association of RASSF1A hypermethylation with risk of HBV/HCV-induced hepatocellular carcinoma: A meta-analysis.
Peng JL; Wu JZ; Li GJ; Wu JL; Xi YM; Li XQ; Wang L
Pathol Res Pract; 2020 Oct; 216(10):153099. PubMed ID: 32853942
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
7. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
[TBL] [Abstract][Full Text] [Related]
8. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?
Mohamed NA; Swify EM; Amin NF; Soliman MM; Tag-Eldin LM; Elsherbiny NM
Arab J Gastroenterol; 2012 Sep; 13(3):111-5. PubMed ID: 23122451
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of DNMT1 mediated by HBx suppresses RASSF1A expression independent of DNA methylation.
Qiu X; Zhang L; Lu S; Song Y; Lao Y; Hu J; Fan H
Oncol Rep; 2014 Jan; 31(1):202-8. PubMed ID: 24247422
[TBL] [Abstract][Full Text] [Related]
10. Long Non-Coding RNA IGF2AS in Serum may be a Biomarker for Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma.
Qi J; Li J; Sun J; Li C
Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850718
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylated Ubiquitin-Conjugating Enzyme2 Q1 (UBE2Q1) Gene Promoter in the Serum Is a Promising Biomarker for Hepatitis B Virus-Associated Hepatocellular Carcinoma.
Hu N; Fan XP; Fan YC; Chen LY; Qiao CY; Han LY; Wang K
Tohoku J Exp Med; 2017 Jun; 242(2):93-100. PubMed ID: 28592717
[TBL] [Abstract][Full Text] [Related]
12. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
[TBL] [Abstract][Full Text] [Related]
13. RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian Patients.
Araújo OC; Rosa AS; Fernandes A; Niel C; Villela-Nogueira CA; Pannain V; Araujo NM
PLoS One; 2016; 11(4):e0153796. PubMed ID: 27078152
[TBL] [Abstract][Full Text] [Related]
14. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
[TBL] [Abstract][Full Text] [Related]
15. Cell-free methylation markers with diagnostic and prognostic potential in hepatocellular carcinoma.
Lu CY; Chen SY; Peng HL; Kan PY; Chang WC; Yen CJ
Oncotarget; 2017 Jan; 8(4):6406-6418. PubMed ID: 28031532
[TBL] [Abstract][Full Text] [Related]
16. Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma.
Mansour LA; El Raziky M; Mohamed AA; Mahmoud EH; Hamdy S; El Sayed EH
Asian Pac J Cancer Prev; 2017 Jun; 18(6):1637-1643. PubMed ID: 28670882
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma.
Xiang L; Chen LM; Zhai YJ; Sun WJ; Yang JR; Fan YC; Wang K
Life Sci; 2021 Apr; 270():119061. PubMed ID: 33454364
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
19. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
[TBL] [Abstract][Full Text] [Related]
20. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA.
Zhang YJ; Wu HC; Shen J; Ahsan H; Tsai WY; Yang HI; Wang LY; Chen SY; Chen CJ; Santella RM
Clin Cancer Res; 2007 Apr; 13(8):2378-84. PubMed ID: 17438096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
